Longeveron (LGVN) Projected to Post Earnings on Wednesday

Longeveron (NASDAQ:LGVN) is expected to post its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.19) per share and revenue of $0.3260 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Longeveron (NASDAQ:LGVN) last released its earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.33 million. Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. On average, analysts expect Longeveron to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Longeveron Trading Up 1.3%

NASDAQ:LGVN opened at $0.75 on Wednesday. Longeveron has a 12 month low of $0.47 and a 12 month high of $1.58. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $0.71 and its 200 day moving average is $0.75. The stock has a market capitalization of $23.42 million, a PE ratio of -0.67 and a beta of -0.31.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new stake in Longeveron Inc. (NASDAQ:LGVN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned 0.32% of Longeveron at the end of the most recent quarter. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on LGVN. Wall Street Zen downgraded Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings upgraded shares of Longeveron from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. HC Wainwright reduced their target price on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, May 4th. Finally, Maxim Group lowered shares of Longeveron from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $5.50.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.